araag2/HINT huggingface dataset:
Clinical trial NCT00258960 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: liposomal doxorubicin, cyclophosphamide, trastuzumab
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must sign an informed consent before of specific procedures of clinical
             trial.

          -  Patients with histologically confirmed breast cancer and overexpression of Her2neu.

          -  Age> 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) equal or < 2.

          -  Patients have not been treated previously with chemotherapy for metastatic disease.

          -  Patients must have at least one measurable lesion according to RECIST criteria.

          -  Patients should have an adequate organ function to tolerate chemotherapy.

        Exclusion Criteria:

          -  Patients with hypersensitivity reactions to any of the medications of the clinical
             trial.

          -  Patients who are pregnant or lactating are not eligible.

          -  Hepatic disease.

          -  Not controlled active infection

          -  Symptomatic metastatic brain cancer

          -  Previous adjuvant treatment with anthracyclines with a total accumulated dose > 300
             mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)
Clinical trial NCT00370747 (phase 2, status: completed)
Conditions: dry eye syndromes
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: ecabet, ecabet, placebo
SMILES: [H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O, [H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male/female at least 18 years of age

          -  Agree to avoid disallowed medications

          -  Have a diagnosis of dry eye

        Exclusion Criteria:

          -  Have chronic systemic inflammation

          -  Have active seasonal ocular allergies
Clinical trial NCT00075504 (phase 2, status: completed)
Conditions: stage ii gallbladder cancer, stage iiia gallbladder cancer, stage iiib gallbladder cancer, stage iva gallbladder cancer, stage ivb gallbladder cancer
ICD codes: C23, D37.6, C23, D37.6, C23, D37.6, C23, D37.6, C23, D37.6
Drugs: triapine, gemcitabine
SMILES: NC(=S)N\N=C\C1=C(N)C=CC=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the biliary ducts that is
             unresectable and/or metastatic; this can include unresectable or metastatic carcinomas
             of the Ampulla of Vater. In addition, unresectable or metastatic gall bladder
             carcinoma will be allowed

          -  Measurable disease

          -  No prior chemotherapy

          -  Life expectancy of greater than 3 months

          -  ECOG performance status =< 2 (Karnofsky >= 60%)

          -  Leukocytes >= 3,000/uL

          -  Absolute neutrophil count >= 1,500/uL

          -  Platelets >= 100,000/uL

          -  Creatinine within normal institutional limits

          -  Patients may have mildly abnormal liver function defined as a total bilirubin > ULN
             and =< 3x the institutional upper limits of normal (includes CTCAE v.3 grades 1-2
             hyperbilirubinemia)

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Triapine or gemcitabine

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia

          -  Uncontrolled pulmonary disease including asthma, chronic bronchitis and COPD or with
             requirements for chronic oxygen use

          -  Pregnant or lactating women

          -  HIV infection

          -  Patients with G6PD deficiency will be excluded in view of the potential for
             methemoglobinemia

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements
Clinical trial NCT00705003 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: bci-024: over-encapsulated buspirone tablet 15 mg qd and bci-049: over-encapsulated melatonin tablet 3 mg qd, bci-024 (buspirone), matching placebo
SMILES: O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects will be male and female subjects between the ages of 18 to 65 meeting the
             Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR)
             criteria for Major Depressive Disorder with a Quick Inventory of Depressive
             Symptomatology-16 Item Self Report (QIDS-SR16) score of >14 at the Screening and
             Baseline Visits.

          -  Female subjects must be on a stable and medically reliable form of birth control, must
             agree to continue use of this birth control during the study, and must have negative
             urine pregnancy tests at the Screening Visit.

        Exclusion Criteria:

          -  Subjects with any other psychiatric Axis-I disorder as a principal diagnosis within 6
             months of screening or subjects with a history of obsessive compulsive disorder,
             psychotic disorder, bipolar disorder, or mental retardation at any time are not
             eligible for the study.

          -  Subjects who pose a suicidal risk or who have a history of eating disorder or
             substance dependence within 6 months of screening, or a history of substance abuse
             within 3 months of screening are also ineligible.

          -  Subjects with clinically significant abnormalities on any Screening or Baseline
             assessments, including laboratory tests, are excluded.

          -  Subjects with a known intolerance to either buspirone or melatonin are excluded, as
             are subjects with clinically significant medical or psychiatric conditions that might
             be detrimental to the subject should they participate in the study.

          -  Subjects who have used selective serotonin reuptake inhibitors (SSRIs) within 2 weeks
             of Screening (within 4 weeks for fluoxetine) are excluded as are subjects requiring
             concomitant use of antipsychotic and anxiolytic medications and any drugs with known
             psychotropic properties. Concomitant medications that are not excluded by the protocol
             and that are taken chronically must be at a stable dosage for at least 4 weeks prior
             to screening.
Clinical trial NCT01152437 (phase 2, status: completed)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bibw 2992, cetuximab
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          1. Patients with metastatic colorectal cancer who have failed both oxaliplatin- and
             irinotecan-based regimens

          2. Tumour sample available for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene
             homolog) mutation testing and other biomarker analyses.

        Exclusion criteria:

          1. Prior treatment with Epidermal Growth Factor Receptor (EGFR) targeting small molecules
             or antibodies.

          2. Biological treatment (including Bevacizumab or any other antiangiogenic agents) during
             the trial is not allowed.

          3. Known pre-existing interstitial lung disease.

          4. Planned major surgical procedures during the trial period.
Clinical trial NCT01089010 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: placebo, 250 mg ck-2017357, 500 mg ck-2017357
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C
Eligibility criteria:

        Inclusion Criteria

        For enrollment, patients were required to satisfy all of the following criteria at
        baseline:

        1. Able to comprehend and willing to sign an Informed Consent Form (ICF)

          1. A diagnosis of familial or sporadic ALS (defined as meeting the possible,
             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS
             according to the World Federation of Neurology El Escorial criteria) (Brooks, Miller
             et al. 2000)

          2. Males or females 18 years of age or older

          3. Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive

          4. Maximum voluntary grip strength in at least one hand between 10 and 40 pounds
             (females) or 10 and 60 pounds (males)

          5. Able to swallow capsules with water

          6. Upright Slow Vital Capacity (SVC) > 40% of predicted for age, height, and sex [See
             Appendix 16.6.1]

          7. Able to perform pulmonary function tests

          8. Pre-study clinical laboratory findings (including troponin I [TnI] and creatine
             phosphokinase [CPK]) within normal range, or, if outside of the normal range, deemed
             not clinically significant by the Investigator

          9. For female patients only: The patient is post-menopausal (≥ 1 year) or sterilized, or
             if she is of childbearing potential, she is not breastfeeding, her pregnancy test is
             negative, she has no intention to become pregnant during the course of the study, and
             she is using contraceptive drugs or devices for the duration of the study and for 10
             weeks after the end of the study.

        For male patients only: Male patients agree for the duration of the study and 10 weeks
        after the end of the study to use a condom during sexual intercourse with female partners
        who are of reproductive potential and to have female partners use an additional effective
        means of contraception (e.g., diaphragm plus spermicide or oral contraceptives) or the male
        patient must agree to abstain from sexual intercourse for 10 weeks after the end of the
        study.

        Exclusion Criteria

        Patients satisfying any of the following criteria at baseline were excluded from
        enrollment:

          1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper
             limit of normal (ULN)

          2. Life expectancy < 3 months

          3. Participation in any trial in which receipt of investigational study drug occurred
             within 30 days prior to dosing

          4. Any prior treatment with CK-2017357

          5. In the opinion of the Investigator, the patient is not suitable to participate in the
             study
Clinical trial NCT00003292 (phase 2, status: terminated)
Conditions: chondrosarcoma, adult fibrosarcoma, adult leiomyosarcoma, adult rhabdomyosarcoma, adult malignant meningioma, adult brain malignant hemangiopericytoma
ICD codes: R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0, R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0
Drugs: ifosfamide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven recurrent or unresectable:

          -  Malignant meningioma

          -  Intracranial hemangiopericytoma

          -  Primary central nervous system sarcoma, including:

          -  Fibrosarcoma

          -  Rhabdomyosarcoma

          -  Chondrosarcoma

          -  Leiomyosarcoma

          -  Measurable or evaluable disease on CT or MRI scan

          -  Persistent disease following biopsy or incomplete resection OR

          -  Recurrent disease following complete resection

          -  No benign meningioma

          -  No prior or current systemic sarcoma

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  SWOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  No myocardial infarction within the past 3 months

          -  No active angina

          -  No unstable heart rhythms

          -  No congestive heart failure

        Other:

          -  HIV negative

          -  No allergy to study drugs

          -  No serious concurrent medical or psychiatric illness

          -  No uncontrolled peptic ulcer disease

          -  No prior malignancy within past 5 years except adequately treated:

          -  Basal or squamous cell carcinoma of the skin

          -  Carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Effective contraception required of fertile patients

        PRIOR CONCURRENT THERAPY:

          -  Recovered from toxic effects of prior therapy and/or from postoperative complications

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior ifosfamide

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent hormonal therapy (except estrogen replacement therapy)

          -  Corticosteroids allowed if dose is stable or decreasing

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

          -  Progressive disease following radiation required

          -  No concurrent radiotherapy

        Surgery:

          -  See Disease Characteristics
Clinical trial NCT00475085 (phase 3, status: completed)
Conditions: nausea
ICD codes: R11.0, R11.11, R11.2
Drugs: aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Have a diagnosis of cancer and be chemotherapy naive.

          -  Must be scheduled to receive a chemotherapy treatment containing doxorubicin
             hydrochloride, epirubicin hydrochloride, cisplatin, carboplatin, or oxaliplatin (any
             dose or schedule) without concurrent radiotherapy or interferon treatment

          -  Chemotherapy may be for adjuvant, neoadjuvant, curative or palliative intent.

          -  Dose-dense regimens (e.g. chemotherapy with doxorubicin or epirubicin given every two
             weeks)are allowed.

          -  For the purposes of this study, Day 1 of chemotherapy will be defined as the day of
             administration of cisplatin, carboplatin, oxaliplatin, doxorubicin or epirubicin.

          -  Regimens with multiple-day doses of doxorubicin, epirubicin, cisplatin, carboplatin,
             oxaliplatin, dacarbazine, hexamethylmelamine, nitrosoureas, or streptozocin are not
             allowed. Chemotherapy agents, other than those listed above, may be given orally,
             intravenously, or by continuous infusion on one or multiple days.

          -  Able to understand English

        Exclusion criteria:

          -  No symptomatic brain metastases

          -  No concurrent or impending bowel obstruction

          -  Regimens containing liposomal doxorubicin or cisplatin are not allowed.

          -  No concurrent pimozide, terfenadine, astemizole, or cisapride

          -  No concurrent doxorubicin hydrochloride liposome or cisplatin

          -  No concurrent multiple-day doses of dacarbazine, altretamine, nitrosoureas,
             streptozocin, cisplatin, carboplatin, or oxaliplatin
Clinical trial NCT00203957 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: istradefylline, istradefylline
SMILES: [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who completed double-blind treatment study 6002-US-0 13, 6002-US-0 18 or
             6002-EU-007, or who discontinued from open-label study 6002-US-007.

          -  Patients who are female must be non-pregnant and non-nursing. Women of Child Bearing
             Potential (WOCBP) must use a reliable method of contraception (e.g., oral
             contraceptive or long-term injectable or implantable hormonal contraceptive, double-
             bather methods, such as condom and diaphragm, condom and foam, condom and sponge or
             intra-uterine devices) and have a negative serum (North American sites) or urine
             (non-North American sites) pregnancy test at screening and at baseline. Women are
             considered to not be of childbearing potential if they have been surgically
             sterilized.

          -  Patients who are able to give written informed consent

        Exclusion Criteria:

          -  Group B Patients who are treated within 30 days before baseline (or five half-lives of
             the compound, if longer) with any investigational agent other than istradefylline

          -  Patients who have a history of a psychotic illness.

          -  Patients who are treated within three months (six months if patient was treated with
             depot) before baseline or during the trial with an anti-psychotic agent.

          -  Patients who are treated with any centrally acting drug that has known dopamine
             antagonist properties at therapeutic doses (e.g., buspirone, amoxapine).

          -  Patients who have atypical parkinsonism.

          -  Patients who have secondary parkinsonism variants.

          -  Patients who have a diagnosis of cancer or evidence of continued malignancy within
             five years of study enrollment (except for patients that have had basal cell carcinoma
             or carcinoma in situ of the cervix surgically excised).

          -  Patients who have a clinically significant illness of any organ system which may
             compromise the safety of the patient during the trial or affect the ability of the
             patient to complete the trial.

          -  Patients who, for any reason, are judged by the Investigator to be inappropriate for
             this trial, including a patient who is unable to communicate or to cooperate with the
             Investigator.

          -  Patients who have an ALT and/or an AST level greater than 1.5 ULN at screening will be
             ineligible to participate in the trial.

          -  Patients who have a history of drug or alcohol abuse or dependence within the last
             year (DSM-IVR).

          -  Patients with significant drug allergies.
Clinical trial NCT00073528 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib, letrozole, placebo
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key inclusion criteria

          1. Signed informed consent;

          2. Subjects with histologically confirmed invasive breast cancer with stage IV disease at
             primary diagnosis or at relapse after curative-intent surgery;

               -  Subjects with either measurable or non-measurable disease per Response Evaluation
                  Criteria in Solid Tumors (RECIST).

               -  If the disease was restricted to a solitary lesion, its neoplastic nature was
                  confirmed by cytology or histology.

          3. Tumors that were ER+ and/or PgR+;

          4. Post-menopausal female subjects ≥ 18 years of age.

          5. ECOG Performance Status of 0 or 1;

          6. Subjects who had archived tumor tissue available to compare tumor response with
             intra-tumoral expression of ErbB1 and ErbB2.

          7. Adjuvant therapy with an aromatase inhibitor and / or trastuzumab was allowed;
             however, treatment was to stop more than 1 year prior (>12 months) to the first dose
             of randomized therapy.

          8. Subjects must have ended hormonal replacement therapy (HRT) at least 1 month (30 days)
             prior to receiving the first dose of randomized therapy.

        Key exclusion criteria:

          1. Pre-menopausal, pregnant, or lactating;

          2. Received prior chemotherapy, hormonal therapy, immunotherapy, biologic therapy, or
             anti-ErbB1/ErbB2 therapy for advanced or metastatic disease;

          3. Bisphosphonate therapy for bone metastases was allowed; however, treatment was to be
             initiated prior to the first dose of randomized therapy. Prophylactic use of
             bisphosphonates in subjects without bone disease, except for the treatment of
             osteoporosis, was not permitted;

          4. Used an investigational drug within 30 days or 5 half-lives, whichever is longer,
             preceding the first dose of randomized therapy (lapatinib or placebo);

          5. Subjects with known history of/clinical evidence of CNS metastases or leptomeningeal
             carcinomatosis; and / or subjects on concurrent anti-cancer therapies other than
             letrozole; and / or who have not recovered from toxicities related to prior adjuvant
             therapy (surgery, radiotherapy, chemotherapy etc.)

          6. Subjects with active or uncontrolled infection and/ or with history of uncontrolled or
             symptomatic angina, arrhythmias, or congestive heart failure.